Clinical practice guideline for the diagnosis and treatment of subclinical thyroid disease;Guía clínica del diagnóstico y tratamiento de la disfunción tiroidea subclínica

Endocrinologia y Nutricion

Volumn 54, Issue 1, 2007, Pages 44-52

  Hernández, Juan José Corrales ^a   Pedrol, Núria Alonso ^a   Blanco, Ana Cantón ^a   Ferrater, Juan Carlos Galofré ^a   Pérez, Antonio ^a   Morales, Teresa Lajo ^a   Corral, Begoña Pérez ^a   Tortosa Henzi, Federic ^a  

^a UNIVERSITY OF LLEIDA   (Spain)

Author keywords

Subclinical hyperthyroidism; Subclinical hypothyroidism; Subclinical thyroid disease

Indexed keywords

ATENOLOL; BISOPROLOL; CARBIMAZOLE; LEVOTHYROXINE; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN; THYROXINE;

CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC TEST; HUMAN; HYPERTHYROIDISM; PRACTICE GUIDELINE; PREGNANT WOMAN; REVIEW; RISK FACTOR; THYROID DISEASE;

EID: 33847717591     PISSN: 15750922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1575-0922(07)71404-3     Document Type: Article

References (34)

1. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-38.
2. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295:1033-41.
3. Wilson GR, Curry RW Jr. Subclinical thyroid disease. Am Fam Physician. 2005;72:1517-24.
4. Papi G, Pearce EN, Braverman LE, Betterle C, Roti E. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only. Am J Med. 2005;118:349-61.
5. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Consensus Statement. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, The American Thyroid Association and The Endocrine Society. J Clin Endocrinol Metab. 2004;90:581-5.
6. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Int Med. 2000;160:526-34.
7. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T4 and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-99.
8. Gasco Eguiluz E, Serna Arnaiz MC, Vázquez Torguet A, Peremiquel Lluch M, Ibarra Excuer M, Serra Majem L. La prevalencia de trastornos funcionales tiroideos en la provincia de Lleida. Aten Primaria. 1999;24:475-9.
9. Díez JJ, Molina I, Ibars MT. Prevalence of thyroid dysfunction in adults over age 60 years from an urban community. Exp Clin Endocrinol Diabetes. 2003;111:480-5.
10. Galofré JC, García-Mayor RVG, Fluiters E, Fernández-Calvet L, Rego A, Páramo C, et al. Incidence of different forms of thyroid dysfunction and its degrees in an iodine sufficient area. Thyroidol Clin Exp. 1994;6:49-54.
11. Sawin CT. Subclinical hyperthyroidism and atrial fibrillation. Thyroid. 2002;12:501-3.
12. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-52.
13. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab. 1996;81:4278-89.
14. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001;134:561-8.
15. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358:861-5.
16. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol. 2005;152:1-9.
17. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. JAMA. 2004;291:239-43.
18. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348:2646-55.
19. Cooper DS. Subclinical hypothyroidism. N Engl J Med. 2001;345:260-5.
20. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharat P. The agin thyroid: thyroid deficiency in the Framingham study. Arch Int Med. 1985;145:1386-8.
21. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab. 2001;86:4860-6.
22. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol. 1995;43:55-68.
23. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270-8.
24. Lindeman RD, Romero LJ, Schade DS, Wayne S, Baumgartner RN, Garry PJ. Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey. Thyroid. 2003;13:595-600.
25. Walsh JP, Bremner AP, Bulsara MK, O'leary P, Leedman PJ, Feddema P, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005;165:2467-72.
26. Rodondi N, Newman AB, Vittinghoff E, De Rekeneire N, Satterfield S, Harris TB, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med. 2005;165:2460-6.
27. Monzani F, Di Bello V, Caraccio N, Bertini A, Giorgi D, Giusti C, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab. 2001;86:1110-5.
28. Danese MD, Ladenson PW, Meinert CL, Powe NR. Effect of thyroixine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literatura. J Clin Endocrinol Metab. 2000;85:2993-3001.
29. Pérez A, Cubero JM, Sucunza N, Ortega E, Arcelus R, Rodríguez-Espinosa J, et al. Emerging cardiovascular risk factors in subclinical hypothyroidism: lack of change after restoration of euthyroidism. Metabolism. 2004;53:1512-5.
30. Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis. 2003;166:379-86.
31. Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, Usa T, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab. 2004;89:3365-70.
32. Gussekloo J, Van Exel E, De Craen AJ, Meinders AE, Frölich M, Westendrop RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004; 292: 2591-2599.
33. Díez JJ. Hipotiroidismo subclínico. Endocrinol Nutr. 2005;52:251-9.
34. Thyroid disease in pregnancy. ACOG Practice Buletin. No. 37. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2002;100:387.